Delayed Graft Function Clinical Trial
Official title:
DRAFFT Trial: Delayed Renal Allograft Function and Furosemide Treatment: A Randomized Prospective Double-blinded Placebo-controlled Clinical Pilot Trial
This study will be a randomized prospective double-blind placebo-controlled clinical pilot trial. This will be a single center project that will take place at Loma Linda University Medical Center. All adult kidney recipients will be informed of the study prior to operation. The Nephrology fellows or attending physicians will attempt to obtain informed consent from all eligible patients, pre-transplant. Those patients who consent will be screened post operation for enrollment. Patients who do not meet all eligibility criteria and/or who meet some exclusion criteria will be deemed ineligible for the trial, and will be excluded. The Nephrology and Transplant teams will be blinded of patient assignment and only the pharmacy will know the patient's assignment.
1. Background/ Rationale Kidney Transplantation is a lifesaving modality in patients with
end-stage renal disease (ESRD), and the numbers of transplants have been skyrocketing
since the first successful trials. In 2013 alone, there were over 18,000 kidney
transplants done in the United States of America. Of those, 11,161 were from a deceased
donor (NKUDIC 2011, One Legacy 2014, USRDS 2013). One common complication of renal
transplants is Delayed Graft Function (DGF). DGF is a serious complication, which is
best defined as the need for renal replacement therapy, such as dialysis, within the
first week after renal transplant (Mallon et al. 2013). DGF greatly increases the risk
of acute and chronic transplant rejection, which decreases patient survival and quality
of life, for those patients who do survive (Perico et al. 2004, Weber et al. 2014).
Additionally, the rate of DGF is highest in patients who have received deceased donor
transplants (One Legacy 2014). Therefore, it is crucial to the well-being of this large
population to reduce the incidence of DGF. Our approach is to investigate current
treatment modalities for patients post-deceased donor renal transplant, to understand
how best to prevent DGF before it even starts. Currently, administration of loop
diuretics such as furosemide is a common practice in order to prevent and treat
oliguria in renal transplant patients. However, only animal models have been able to
show a benefit in treating acute kidney injury (AKI), which occurs in the transplant
kidney due to cold ischemia time, with furosemide. There is a lack of evidence that
furosemide use leads to improved patient outcomes in patients with AKI (Nadeau-Fredette
et al. 2013). Given that side effects of furosemide administration include ototoxicity,
hypotension, electrolyte abnormalities, and hypersensitivity reactions, and the
investigators hypothesize, may not significantly reduce the incidence of DGF from
placebo, it is important to investigate if the benefits of furosemide administration
truly outweigh the harms (Strom et al. 2003). The investigators intend to achieve this
by way of a randomized, double-blinded, pilot clinical trial in adult oliguric
patients, post-deceased donor renal transplant.
2. Objectives
I.Primary Objective:
i.To test the hypothesis that DGF rate is the same in adult oliguric post-deceased donor
renal transplant patients administered furosemide vs. placebo.
II.Secondary Objectives:
i.To compare the following within the two treatment groups:
- 30-day, 90-day and 12-month creatinine levels and estimated glomerular filtration rate
(eGFR)
- The need for RRT (Hemodialysis or Peritoneal dialysis) 30 days, 90 days and 12 months
post-transplant
- The time from transplant to DGF development
- The incidence of DGF
- The incidence of primary graft non-function
- Overall hospital length of stay
- The KDPI score in relation to primary graft non-function
ii. To quantify the association between furosemide administration and relevant patient
centered outcomes, such as hospital length of stay and acquired complications, in order to
decrease patient morbidity and mortality.
c. Study Outline
All patients that have been admitted for a deceased donor kidney transplant will be seen by
the Nephrology service for pre-transplant evaluation. The Nephrology Fellow/Attending
physician will go over a checklist that determines if the patient will be eligible for the
study and will obtain the informed consent if the patient is eligible. Informed consent will
be obtained from all eligible patients. All eligible patients' urine output will be
monitored as soon as they return to the unit from the operating room. If the patient remains
oliguric or anuric for 6 hours, the bedside nurse will alert the on-call study coordinator
for randomization and enrollment per protocol.
Study Intervention Patients assigned to the furosemide infusion group will receive
furosemide infusions, as outlined in figure 2. This has been adapted from Ostermann et al.
(2007) and the SPARK study protocol (Bagshaw et al. 2010).
Furosemide will be prepared in bags that contain 1000 mg of furosemide per 250 mL of saline
reaching a concentration of 4 mg/mL. All medication and placebo bags will have no
identifiers that show what type of drug is being administered, for blinding purposes.
Medication and placebo bags will have randomly generated study identifier numbers. The
protocol in figure 2 will be followed to achieve a total urine output of 1mL/kg/h. The
furosemide infusion rate will not exceed 4mg/min IV as this is the maximum set by the
manufacturer.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02134314 -
C1INH Inhibitor Preoperative and Post Kidney Transplant to Prevent DGF & IRI
|
Phase 1/Phase 2 | |
Completed |
NCT02346968 -
Evaluation of CAF22 After Renal Transplantation
|
||
Completed |
NCT01794663 -
Placebo-Controlled Study to Evaluate the Safety and Efficacy of OPN-305 in Preventing Delayed Renal Graft Function
|
Phase 2 | |
Completed |
NCT00298181 -
YSPSL for Prevention of Delayed Graft Function Part A
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05166460 -
Novel Cooling Device for the Elimination of Warm Ischemia During Renal Transplantation
|
N/A | |
Recruiting |
NCT03071536 -
Furosemide Stress Test Predicting Early Graft Function in Kidney Transplantation
|
N/A | |
Not yet recruiting |
NCT05513807 -
Graft Acute Kidney Injury: Vitamin B3 to Facilitate Renal Recovery In the Early Life of a Transplant
|
Phase 3 | |
Recruiting |
NCT04005469 -
Safety and Efficacy of Treprostinil (Remodulin®) In Reducing Ischemia-Reperfusion Injury During Kidney Transplantation
|
Phase 1/Phase 2 | |
Completed |
NCT01848249 -
Deceased Donor Biomarkers and Recipient Outcomes
|
||
Active, not recruiting |
NCT02474667 -
Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney
|
Phase 3 | |
No longer available |
NCT02026934 -
CliniMACS® CD34+ Reagent System for Expanded Access Use
|
N/A | |
Terminated |
NCT00217152 -
A Kidney Transplant Study to Look at the Effects of Taking Fixed Doses of CellCept Versus Taking Doses of CellCept Based on the Concentration of CellCept in the Blood When Taking Full or Reduced Dose Calcineurin Inhibitors
|
Phase 4 | |
Recruiting |
NCT05430620 -
Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys
|
Phase 3 | |
Completed |
NCT03864926 -
Envarsus in Delayed Graft Function (E-DGF)
|
Phase 4 | |
Recruiting |
NCT06367205 -
Norepinephrine Infusion Combined With Goal-directed Fluid Therapy in Patients Undergoing Kidney Transplantations
|
N/A | |
Completed |
NCT02610296 -
QPI-1002 for Prevention of Delayed Graft Function in Recipients of an Older Donor Kidney Transplant
|
Phase 3 | |
Active, not recruiting |
NCT02568696 -
Intra-graft Coagulation Events in Clinical Renal Transplantation and Delayed Graft Function
|
||
Recruiting |
NCT01837043 -
Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function
|
Phase 2 | |
Terminated |
NCT01878786 -
A Pilot Study Comparing the Safety and Efficacy of Everolimus With Other Medicines in Recipients of ECD/DCD Kidneys
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT01395719 -
Context - Remote Ischemic Conditioning in Renal Transplantation - Effect on Immediate and Extended Kidney Graft Function
|
N/A |